Beckman's Stock Drops on Missed Q2 Targets | GenomeWeb
NEW YORK (GenomeWeb News) – Shares in Beckman Coulter were down approximately 7.7 percent, or $4.39, at $52.61 in mid-afternoon trading today after the company reported a decrease in second-quarter sales and net income.
As reported by GenomeWeb News this morning, total revenues declined to $616 million, from $619 in the same period last year. Beckman blamed the lower-than-expected revenues on lagging sales in the Asian market.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.